More clinical experience and multiple clinical trials (including those that enrolled patients with CKD) have highlighted the fact that patients treated with SGLT2 inhibitors are significantly less likely to experience acute kidney injury than patients treated with placebo.29 This evidence concerns the gene SLC5A2 and acute kidney injury.